Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A major clinical trial finds that a 3.5-week radiation course after mastectomy is just as safe and effective as the traditional 5-week regimen — even for women undergoing breast reconstruction. The RT CHARM trial enrolled nearly 900 patients and found no meaningful difference in reconstruction complications, cancer recurrence, or serious side effects. This could be a game-changer for how post-mastectomy radiation is delivered.
For years, women undergoing mastectomy with breast reconstruction were stuck with a grueling 5- to 6-week radiation schedule — simply because no one had rigorously tested a shorter alternative for them. The randomized phase 3 RT CHARM trial, now published in the Journal of Clinical Oncology, changes that. It found that a 3.5-week (16-fraction) course of hypofractionated postmastectomy radiation therapy (PMRT) is noninferior to the conventional 5-week (25-fraction) course in women with unilateral invasive breast cancer planning breast reconstruction.
The trial enrolled 898 patients between 2018 and 2021, with a median follow-up of nearly 4 years. Reconstruction complication rates — covering wound healing issues, readmissions, and unplanned reoperations — were comparable between the two groups, and recurrence rates showed no statistically significant difference. Notably, the shorter regimen was associated with less acute dermatitis.
By the Numbers:
Why it matters: Shorter radiation means fewer hospital visits, less time away from work, and lower costs — without sacrificing safety or effectiveness. Many centers have already begun shifting their practice, and these published results are expected to accelerate that transition broadly.
